129816-30-4

Usage

Uses

Used in Research Applications:
Uridine, 2'-deoxy-5'-O-[(1,1-dimethylethyl)dimethylsilyl]-5-fluorois used as a research tool for studying the structure and function of RNA and DNA. The modifications in its structure allow scientists to investigate the effects of these changes on the molecules' properties, such as stability and binding affinity.
Used in Therapeutic Applications:
This modified nucleoside is used as a potential therapeutic agent, particularly in the development of nucleoside-based drugs. The altered properties of RNA and DNA, resulting from the incorporation of this modified nucleoside, may offer new avenues for treating various diseases and conditions.
Used in Drug Development Industry:
Uridine, 2'-deoxy-5'-O-[(1,1-dimethylethyl)dimethylsilyl]-5-fluorois used as a key component in the development of novel nucleoside-based drugs. Its unique structure and properties make it a valuable candidate for creating new therapeutic agents that can target specific biological processes and pathways.

Upstream product

• 18162-48-6 tert-butyldimethylsilyl chloride 
• 50-91-9 5-Fluoro-2'-deoxyuridine 
• 288-32-4 1H-imidazole 

Downstream Products

• 129802-14-8 5'-O-(tert-butyldimethylsilyl)-2'-deoxy-5-fluoro-3'-O-(p-toluenesulfonyl)uridine 
• 150109-60-7 1-[(2R,4S,5R)-5-(tert-Butyl-dimethyl-silanyloxymethyl)-4-(4-fluoro-benzyloxy)-tetrahydro-furan-2-yl]-5-fluoro-1H-pyrimidine-2,4-dione 
• 150109-58-3 1-[(2R,4S,5R)-5-(tert-Butyl-dimethyl-silanyloxymethyl)-4-(4-chloro-benzyloxy)-tetrahydro-furan-2-yl]-5-fluoro-1H-pyrimidine-2,4-dione 
• 677723-34-1 3'-O-(3-benzenesulfonylfuroxan-4-yl)-5'-O-(tert-butyldimethylsilyl)-5-fluoro-2'-deoxyuridine 
• 232925-20-1 5-fluoro-2'-deoxyuridine 5'-O-[phenyl N-(methoxy-(S)-alaninyl)phosphate] 

Relevant academic research and scientific papers

FLOXURIDINE SYNTHESIS

The present invention relates to a process for the preparation of floxuridine, said process comprising reacting a compound of Formula la with a compound of Formula lla in the presence of an acid Al to provide a compound of Formula Ilia in substantially diastereomerically pure form. Floxuridine may be useful as an anti-cancer drug. Floxuridine may also be useful in the preparation of other anti-cancer drugs, e.g. NUC-3373.

A hydrophilic medicament phospholipid compound, its pharmaceutical composition and application

The invention discloses a phospholipid compound of hydrophilic drugs as well as a pharmaceutical composition and application of the phospholipid compound. The pharmaceutical composition of the phospholipid compound of the hydrophilic drugs or a combined pharmaceutical composition of the phospholipid compound of the hydrophilic drugs and a pharmacologically acceptable carrier; and the pharmaceutical composition is in the form of a liquid preparation, a solid preparation, a semisolid preparation, a capsule, granules, a gel or an injection. The pharmaceutical composition is in the form of liposome nanoparticles prepared from the phospholipid compound of the hydrophilic drugs or the phospholipid compound of the hydrophilic drugs and adjuvants, and the pharmaceutical composition is 10-1000nm in grain size. The phospholipid compound of the hydrophilic drugs and the liposome nanoparticles thereof can serve as a liquid preparation, a solid preparation, a semisolid preparation, a sterilized preparation and a sterile preparation; and the phospholipid compound of the hydrophilic drugs and the liposome nanoparticles thereof are low in toxicity, and are applicable to the efficient treatment of various tumors and the like.

Synthesis and anticancer activity of some 5-fluoro-2′-deoxyuridine phosphoramidates

Two series of novel 4-chlorophenyl N-alkyl phosphoramidates of 3′-O-(t-butoxycarbonyl)-5-fluoro-2′-deoxyuridine (3′-BOC-FdU) (9a-9j) and 5-fluoro-2′-deoxyuridine (FdU) (10a-10j) were synthesized by means of phosphorylation of 3′-BOC-FdU (4) with 4-chlorop

3'- O - And 5'- O -Propargyl Derivatives of 5-Fluoro-2'-Deoxyuridine: Synthesis, Cytotoxic Evaluation and Conformational Analysis

A series of new 3'-O- and 5'-O-propargyl derivatives of 5-fluoro-2'-deoxyuridine (1-4) was synthesized by means of propargyl reaction of properly blocked nucleosides (2,4), followed by the deprotection reaction with ammonium fluoride. The synthesized propargylated 5-fluoro-2'-deoxyuridine analogues (1-4) were evaluated for their cytotoxic activity in three human cancer cell lines: cervical (HeLa), oral (KB) and breast (MCF-7), using the sulforhodamine B (SRB) assay. The highest activity and the best SI coefficient in all of the investigated cancer cells were displayed by 3'-O-propargyl-5-fluoro-2'-deoxyuridine (1), and its activity was higher than that of the parent nucleoside. The other new compounds exhibited moderate activity in all of the used cell lines.

Design and Synthesis of 3′- and 5′ -O-(3-Benzenesulfonylfuroxan-4-yl)-2′-deoxyuridines: Biological Evaluation as Hybrid Nitric Oxide Donor-Nucleoside Anticancer Agents

A group of 3′-O- and 5′ -O-(3-benzenesulfonylfuroxan-4-yl)-2′-deoxyuridines possessing a variety of substituents (H, Me, I, F, CF3) at the C-5 position of the nucleoside moiety were synthesized for evaluation as hybrid anticancer agents that ha

Synthesis and biological activity of O-alkyl-3-N-aminoacyloxymethyl-5- fluoro-2'-deoxyuridine derivatives

In an attempt to improve the effectiveness of action of 5-fluoro-2'- deoxyuridine (FUdR), various kinds of O-alkylated water-soluble analogues were synthesized. Antitumor activities against sarcoma 180 (solid) were also evaluated. Some compounds exhibited potent activities. In particular, 3'-O- p-chlorobenzyl-3-N-aminoacyloxy-methylester derivatives were effective over a very wide range of dose and gave extremely large therapeutic ratios compared with known 5-fluorouracil (5-FU) derivatives.